Ρευματολογικο ιατρειο


   Dr. ελευθεριοσ πελεχασ, PhD, MSC, MAC, rhmsus

1. Tsigaridas N, Troganis E, Pelechas E. Ischemic Colitis, Medical annals of northwestern Greece, 2011;7(2):50-57.


2. Pelechas E, Azoicai D. Improvement of Gastroesophageal reflux in patients with obstructive sleep apnoea treated with continuous positive airway pressure, J Gastrointestin Liver Dis. 2012 Dec;21(4):443 (Indexed in PubMed – IF: 1,891).


3. Tsigaridas N, Pelechas E. Rash in association with fever – Clinical case of non-Hodgkin T-lymphoma, Medical annals of northwestern Greece, 2012;8(2):9-14.


4. Pelechas E, Azoicai D. Gastroesophageal Reflux Disease: epidemiological data, symptomatology and risk factors, Revista Medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, Romania, 2013 Jan;117(1):183-188.


5. Pelechas E, Antoniadis A. A comparative study of job satisfaction between two regional hospitals in Greece, Archives of Hellenic Medicine, 2013 May;30(3):325-334.


6. Pelechas E, Azoicai D. Impact of nasal Continuous Positive Airway Pressure on Heart Rhythm in patients with Obstructive Sleep Apnea/Hypopnea syndrome,

Minerva Medica, 2014;105(3):255-60 (Indexed in PubMed – IF: 1,878).


7. Pelechas E, Tsigaridas N, Papadimitriou I, Kyrama S, Troganis E, Kavvadias A, Karagianni P, Manatou Ch, Tsapogas P. Hospitalized elderly patients due to infection and factors associated with mortality, Medical annals of northwestern Greece, 2014;10(1):66-71.


8. Tsigaridas N, Pelechas E, Kyrama S, Papadimitriou I, Manatou Ch, Tsapogas P. Insulin and heparin administration for the treatment of hypertriglyceraemic pancreatitis, Medical annals of northwestern Greece, 2014;10(1):37-42.


9. Pelechas E, Kavvadias A, Karagianni P, Tsigaridas N, Manatou C, Tsapogas P. Tylosis palmaris et plantaris familiaris in association with Dupuytren’s contracture – A case of ectodermal anomaly, Archives of Hellenic Medicine, 2015;32(1):106-110.


10. Tsigaridas N, Naka K, Tsapogas P, Pelechas E, Damigos D Spinal cord stimulation in refractory angina A systematic review of randomized controlled trials, Acta Cardiologica, 2015;70(2):233-243 (IF: 0,653)


11. Pelechas E, Tsigaridas N, Kyrama S, Trogganis E and Kardamis Ch. Electrocardiographic Manifestations in Three Psychiatric Patients with Hypothermia – Case Report. Hellenic Journal of Cardiology 2016;1(2):1007-9 (doi 10.1016/j.hjc.2015.06.003, IF: 1,229).


12. Pelechas E and Drosos AA. Scleroderma: a progressive insidious disease The Doctor 2016;22:81-82.


13. Pelechas E and Karagianni P. Fibromyalgia and Sleep Disturbance: A Vicious Circle. Austin Arthritis. 2016; 1(3):1013.


14. Pelechas E, Gerolymatou N, Voulgari PV, Drosos AA. Transfusion-related acute lung injury in a patient with systemic lupus erythematosus. Clin Exp Rheumatol 2017 Jan 27 (Epub ahead of print – PMID 28134082 – IF: 2,724).


15. Kaltsonoudis E, Pelechas E, Drosos AA. Dermatomyositis sine myositis – Case presentation. Mediterr J Rheumatol 2017;28(1):67-8.


16. Pelechas E, Voulgari PV, Drosos AA. Sirukumab: a promising therapy for rheumatoid arthritis. Expert Opin Biol Ther. 2017 Apr 4. doi: 10.1080/14712598.2017.1315099 [Epub ahead of print – PMID 28374627 – IF: 3.438).


17. Pelechas E. JAK inhibitors: a promising direction for treating Rheumatoid Arthritis. Int J Pharm Sci Dev Res 2017;3(1):29.


18. Archimandriti D, Iliou C, Tzallas AT, Pelechas E, Drosos AA, Voulgari PV. Comparison of tuberculin skin test and interferon-gamma release assay screening in patients with Rheumatoid Arthritis starting anti-tumor necrosis factor therapy. Annals of the Rheumatic Diseases, 2017;76(suppl 2):1193, doi: 10.1136/annrheumdis­2017­eular.6400 (IF: 12.811).


19. Tsirves G, Voulgari PV, Archimandriti D, Pelechas E, Asimakopoulos D, Drosos AA. Inner ear involvement in Systemic Rheumatic Diseases. Annals of the Rheumatic Diseases, 2017;76(suppl 2):1217, doi: 10.1136/annrheumdis­2017­eular.4805 (IF: 12.811).


20. Pelechas E, Kavvadias A, Tsigaridas N, Karagianni P, Tsapogas P. Henoch-Schonlein Purpura in an Adult 53 years old. Archives of Clinical and Medical Case Reports, 2017;1(1):1-3.


21. Pelechas E, Memi T, Voulgari PV, Drosos AA. A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor. Rheumatol Ther October 11 2017, doi: 10.1007/s40744-017-0084-0 (PubMed ID: 29022197)


22. Pelechas E, Drosos AA. Hydroxychloroquine-induced dark butterfly rash in a rheumatoid arthritis patient. Rheumatology (Oxford) October 23 2017, doi: 10.1093/rheumatology/kex388 (IF: 4.818).


23. Pelechas E, Voulgari PV, Drosos AA. ABP 501 for the treatment of Rheumatoid Arthritis. Expert Opin Biol Ther. 2018 Jan 19. doi: 10.1080/14712598.2018.1430760 [Epub ahead of print – PMID 29350566 – IF: 3.684).


24. Pelechas E, Zouzos G, Voulgari PV, Drosos AA. An uncommon presentation of Granulomatosis with Polyangiitis. Mediterr J Rheumatol 2018;29(1):38-40.


25. Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. Unmet needs in the treatment of Rheumatoid Arthritis. An observational study and a real-life experience from a single university center. Semin Arthritis Rheum. In Press. Available online 22 June 2018. doi: 10.1016/j.semarthrit.2018.06.003 (IF: 4.498).


26. [Acknowledgement] Migkos MP, Somarakis GP, Markatseli TE, Voulgari PV, Drosos AA. Epidemiological characteristics of psoriatic arthritis. Clin Exp Rheumatol 2018 Oct 8 [Epub ahead of print].


27. Pelechas E, Papoudou-Bai A, Voulgari PV, Drosos AA. Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review. Rheumatol Int 2018, doi: 10.1007/s00296-018-4212-0 (IF: 1.952).


28. Pelechas E, Drosos AA. Etanercept Biosimilar SB-4. Expert Opin Biol Ther 2019 Jan 8. Doi: 10.1080/14712598.2019.1566456 (IF: 3.974).


29. Pelechas E, Kaltsonoudis E, Voulgari PV, Drosos AA. Unmet needs in the treatment of ankylosing spondylitis: a long-term observational study from a single university center. Rheumatol Int 2019. Doi: 10.1007/s00296-019-04277-w (IF: 1.952).


30. Pelechas E, Voulgari PV, Drosos AA. Golimumab for Rheumatoid Arthritis. J Clin Med 2019;8(3):387 doi: 10.3390/jcm8030387 (IF: 5.583).


31. Kaltsonoudis E, Pelechas E, Papoudou-Bai A, Markatseli TE, Elisaf M, Voulgari PV, Drosos AA. The impact of temporal artery biopsy for the diagnosis of giant cell arteritis in clinical practice in a tertiary university hospital. PLoS One 2019;14(3):30210845. doi: 10.1371/journal.pone.0210845 (IF: 2.766)


32. Drosos AA, Pelechas E, Voulgari PV. Conventional radiography of the hands and wrists in rheumatoid arthritis. What a rheumatologist should know and how to interpret the radiological findings. Rheumatol Int. 2019 May 22. Doi: 10.1007/s00296-019-04326-4 (IF: 1.952)


33. Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. Comment on: Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry. Rheumatology (Oxford) 2019 Jun 6. doi: 10.1093/rheumatology/kez206. (IF: 5.245)


34. Tsirves GK, Voulgari PV, Pelechas E, Asimakopoulos AD, Drosos AA. Cochlear involvement in patients with systemic autoimmune rheumatic diseases: a clinical and laboratory comparative study. Eur Arch Otorhinolaryngol 2019 May 30. doi: 10.1007/s00405-019-05487-5. (IF: 1,546)


35. Pelechas E, Karagianni P, Karatzeni S, Karavoulia E. Chemotherapy-induced palmo-plantar erythrodysesthesia and leukonychia striata in a systemic lupus erythematosus patient. Fortune J Rheumatol 2019;1(1):007-008.


36. Pelechas E, Memi T, Gerolymatou N, Zouzos G, Karagianni P. Corticosteroids as a cause of Catastrophic Rheumatoid Arthritis. Fortune J Rheumatol 2019;1(1):015-017.


37. Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. Maintained Clinical remission in Ankylosing Spondylitis patients switched from reference Infliximab to its biosimilar: An 18-month comparative open-label study. J Clin Med. 2019;8(7):956. doi:10.3390/jcm8070956 (IF: 5,688)


38. Drosos AA, Pelechas E, Voulgari PV. Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs? J Clin Med. 2019;8(8):pii:E1237. doi: 10.3390/jcm8081237 (IF: 5,688)


39. Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. Reply to the Editor. Semin Arthritis Rheum. 2019 Aug 1. pii: S0049-0172(19)30477-9. doi: 10.1016/j.semarthrit.2019.07.005 (IF: 5,072)


40. Pelechas E, Voulgari PV, Drosos AA. Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag. 2019;15:1073-1079 (IF: 1,824)


41. Pelechas E. Diagnosis and Management of systemic lupus erythematosus – educational quiz. Doctors.net.uk. 2020


42. Drosos AA, Pelechas E, Voulgari PV. Treatment strategies are more important than drugs in the management of rheumatoid arthritis. Clin Rheumatol (2020). https://doi.org/10.1007/s10067-020-05001-x (IF: 2,293)


43. Pelechas E, Karagianni P. Autologous hematopoietic stem cell transplantation in systemic sclerosis patients. J Stem Cell Ther Transplan. 2020;4:001-002. doi: 10.29328/journal.jsctt.1001019.


44. Pelechas E, Memi T, Markatseli TE, Voulgari PV, Drosos AA. Adalimumab-induced Myasthenia Gravis: case-based review. Rheumatol Int. doi: 10.1007/s00296-020-04587-4 (IF: 2,2).


45. Drosos AA, Pelechas E & Voulgari PV. Radiological findings of the Cervical Spine in Rheumatoid Arthritis Patients: What a Rheumatologist should Know. Curr Rheumatol Rep. 2020;22:19. doi: 10.1007/s11926-020-00894-8 (IF: 3,7).


46. Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. Neuroinflammatory events after anti-TNFα therapy. Ann Rheum Dis Epub ahead of print: 20 May 2020. Doi: 10.1136/annrheumdis-2020-217723 (IF: 14,2)


47. Pelechas E, Kosta P, Voulgari PV, Drosos AA. Bertolotti syndrome: a not-to-miss cause of chronic low back pain in young adults. Acta Reumatol Port 2020;45(1):58-60 (IF: 0.7).


48. Pelechas E, Karagianni P. Rheumatoid arthritis: Treatment evolution over the years. Open J Pharmacol Pharmacother 2020;5(1):024-026. doi: 10.17352/ojpp.000013.


49. Venetsanopoulou AI, Pelechas E, Voulgari PV, Drosos AA. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatol Int 2020. doi: https://doi.org/10.1007/s00296-020-04616-2 (IF: 2.2)


50. Drosos AA. Pelechas E, Kaltsonoudis E, Voulgari PV. Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment. Curr Rheumatol Rep. 2020;22:44. doi: https://doi.org/10.1007/s11926-020-00921-8 (IF: 3.7)


51. Alamanos Y, Pelechas E, Voulgari PV, Drosos AA. Incidence of spondyloarthritis and its subtypes: a systematic review. Clin Exp Rheumatol. 2020 Sep 4. (IF: 3.319)


52. Pelechas E, Drossou V, Voulgari PV, Drosos AA. Anti-Rheumatic drugs for the fight against the novel coronavirus infection (SARS-CoV-2). What is the evidence? Mediterr J Rheumatol 2020;31(Suppl 2):259-67.


53. Pelechas E, Kaltsonoudis E, Voulgari PV, Drosos AA. Biosimilars and retention rates in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2020 Oct 18 (IF: 3.319).


54. Pelechas E, Voulgari PV, Drosos AA. Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis. Expert Opin Pharmacother. doi: https://doi.org/10.1080/14656566.2020.1796969 (IF: 2.878).


55. Pelechas E, Voulgari PV, Drosos AA. Preclinical discovery and development of adalimumab for the treatment of rheumatoid arthritis. Expert Opin Drug Discovery. 2020. Doi: 10.1080/17460441.2021.1846516 (IF: 4.887).


56. Pelechas E, Voulgari PV, Drosos AA. Occupational mimics of rheumatoid arthritis: hair dye-induced arthritis. Rheumatol Int. 2020. doi: https://doi.org/10.1007/s00296-020-04748-5 (IF: 2,2).


57. Pieta A, Pelechas E, Gerolymatou N, Voulgari PV, Drosos AA. Calcified constrictive pericarditis resulting in tamponade in a patient with systemic lupus erythematous. Rheumatol Int. 2020. doi: 10.1007/s00296-020-04747-6 (IF: 2,2).


58. Pelechas E, Papoudou-Bai A, Voulgari PV, Drosos AA. Cutaneous autoimmune phenomena of the anti-TNFa biosimilars. Case-based review. Curr Rheumatol Rev. 2020. doi: 10.2174/1573397116666201119151349 (IF: 1.52)


59. Georgiadis AN, Pelechas E, Voulgari PV, Drosos AA. Correspondence on "Cardiovascular effects of biological versus csDMARD therapy in treatment naive, early rheumatoid arthritis". Ann Rheum Dis. 2021. doi: 10.1136/annrheumdis-2021-219891 (IF: 16.1)


60. Pelechas E, Voulgari PV, Drosos AA. Insulin resistance in patients with Rheumatoid Arthritis. Rheumatol Int. 2021 Feb 26. doi: 10.1007/s00296-021-04814-6 (IF: 2.2)


61. Migkos MP, Kaltsondouis E, Pelechas E, Drossou V, Karagianni PG, Kavvadias A, Voulgari PV, Drosos AA. Use of conventional synthetic and biological disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. Rheumatol Int. 2021 March 3. doi: 10.1007/s00296-021-04818-2. (IF: 2.2)


62. Pelechas E, Georgiadis AN, Voulgari PV, Drosos AA. Methotrexate and interstitial lung disease. Is there a real causative factor? Rheumatol Int 2021 May 7. doi: 10.1007/s00296-021-04901-8 (IF: 2.2)


63. Pelechas E, Drossou V, Voulgari PV, Drosos AA. COVID-19 in patients with gout on colchicine. Rheumatol Int. 2021;41(8):1503-1507. doi: 10.1017/s00296-021-04902-7 (IF: 2.2)


64. Drosos AA, Pelechas E, Kaltsonoudis E, Markatseli TE, Voulgari PV. Biologic Therapies and autoimmune phenomena. Mediterr J Rheumatol. 2021;32(2):96-103. doi: 10.31138mjr.32.2.96


65. Drosos AA, Pelechas E, Georgiadis AN, Voulgari PV. A not-to-miss cause of severe cervical spine pain in a patient with Rheumatoid Arthritis: a case-based review. Mediterr J Rheumatol. 2021;in press.


66. Skalkou A, Pelechas E, Voulgari PV, Drosos AA. TNF-induced Lupus. A Case-Based Review. Curr Rheumatol Rev. 2021 Nov 1. doi: 10.2174/157339711666211102094330


67. Tsamis KI, Boutsoras C, Kaltsonoudis E, Pelechas E, Nikas IP, Simos YV, Voulgari PV, Sarmas I. Clinical features and diagnostic tools in idiopathic inflammatory myopathies. Crit Rev Clin Lab Sci. doi: 10.1080/10408363.2021.2000584 (IF: 4,677).


68. Drosos AA, Pelechas E, Voulgari PV. Seronegative Erosive Arthritis Following SARS-CoV-2 Infection. Rheumatol Ther November 2021. Doi: 10.1007/s40744-021-00395-9 (IF: 3,494)


69. Drosos AA, Pelechas E, Georgiadis AN, Voulgari PV. A not-to-miss cause of severe cervical spine pain in a patient with rheumatoid arthritis: a case-based review. Mediterr J Rheumatol. 2021;32(3):256-263


70. Drosos AA, Pelechas E, Drossou V, Voulgari PV. Colchicine against SARS-CoV-2 infection: What is the evidence? Rheumatol Ther.  2022 Feb 2;1-11. doi: 10.1007/s40744-022-00425-0 (IF: 3.615)


71. Drosos AA, Pelechas E, Voulgari PV. A patient with symmetrical poly arthritis. The value of conventional radiography for a correct diagnosis. Rheumatol Ther. 2022 Feb 3:1-11. doi. 10.1007/s40744-022-00426-z (IF: 3.615)


72. Drosos AA, Pelechas E, Voulgari PV. Long COVID from rheumatology perspective: a simple mimicker or promoter of autoimmunity? Clin Rheumatol. 2022 Feb 11. doi: 10.1007/s10067-022-06092-4 (IF: 2.98)


73. Karassa FB, Pelechas E, Zouzos G. The immunogenetics of Vasculitis. Adv Exp Med Biol. 2022;1367:299-334. Doi: 10.1007/978-3-030-92616-8_11 (IF: 2,6)


74. Pelechas E, Drosos AA. State-of-the-art glucocorticoid-targeted drug therapies for the treatment of rheumatoid arthritis. Expert Opinion Pharmacother. 2022 Mar 22;1-9. doi: 10.1080/14656566.2022.2049238 (IF: 3.894)


75. Pelechas E, Drossou V, Voulgari PV, Drosos AA. Anti-Rheumatic Drugs May Ameliorate the Clinical Course and Outcome of COVID-19 in Rheumatoid Arthritis Patients. Mediterr J Rheumatol 2022;33(1):68-74. Doi: 10.31138/mjr.33.1.68


76. Pelechas E, Voulgari PV, Drosos AA. TNFα inhibitor biosimilars associated with alopecia areata. Case-based review. Rheumatol Int. 2022 Apr 16. Doi: 10.1007/s00296-022-05129-w (IF: 2.2)


77. Drosos AA, Pelechas E, Voulgari PV. Treatment strategies of Covid-19. A rheumatology perspective. Eur J Int Med. 2022 May 12. Doi: 10.1016/j.ejim.2022.05.014 (IF: 4.624)


78. Pelechas E, Drossou V, Voulgari PV, Drosos AA. Anti-Rheumatic drugs may ameliorate the clinical course and outcome of COVID-19 in rheumatoid arthritis patients. Mediterr J Rheumatol. 2022;33(1):68-74. Doi: 10.31138/mjr.33.1.68


79. Drosos AA, Pelechas E, Drossou V, Voulgari PV. A response to: letter to the Editor regarding the article: “colchicine against SARS-CoV-2 infection: What is the Evidence?”. Rheumatol Ther. 2022 May 27:1-3. Doi: 10.1007/s40744-022-00457-6 (IF: 3.615)


80. Drosos AA, Pelechas E, Voulgari PV. Biological therapies: induced autoimmune adverse manifestations. Adv Pharmacoepidemiol Drug Saf 2022;11:264. Doi: 10.35248/2167-1052.22.11.264.


81. Drosos AA, Pelechas E, Venetsanopoulou AI, Voulgari PV. Comment on: Palindromic rheumatism following COVID-19 infection evolved to rheumatoid arthritis after COVID-19 reinfection. Clin Exp Rheumatol. 2022 Jul 26. Doi: 10.55563/clinexprheumatol/ykoobe (IF: 4.862)


82. Karassa FB, Bougioukas KI, Pelechas E, Skalkou A, Argyriou E, Haidich A-B. Pharmacological treatment for connective tissue disease-associated interstitial lung involvement: Protocol for an overview of systematic reviews and meta-analyses. PLoS One. 2022 Aug 3;17(8):e0272327. Doi: 10.1371/journal.pone.0272327 (IF: 3,24)


83. Pelechas E, Kaltsonoudis E, Karagianni P, Voulgari PV, Drosos AA. The adulthood transition of patients with polyarticular juvenile idiopathic arthritis in the era of biologic agents. Paediatric Rheumatol 2022;20(Suppl 2):50 (IF: 3,0)


84. Drosos AA, Pelechas E, Venetsanopoulou AI, Voulgari PV. Comment on the Article "Adalimumab-induced Lupus Nephritis: Case Report and Review of the Literature" Eur J Rheumatol. 2022 Dec 8. doi: 10.5152/eurjrheum.2022.22055


85. Zarachi A, Pelechas E, Tsikou A, Kalambokis GN, Zioga A, Panteli KE, Rapti I, Filippas-Ntekouan S, Kastanioudakis I, Karassa FB. Immune-mediated inner ear disease associated with type 1 autoimmune hepatitis: a challenging coexistence. Mediterr J Rheumatol 2022;33(3):349-360. Doi: 10.31138/mjr.33.3.349


86. Migkos M, Kaltsonoudis E, Tziortzioti Z, Pelechas E, Kougkas N, Garyfallos A, Voulgari PV, Drosos AA. Clinical course in COVID 19 disease in immunosuppressed patients diagnosed with rheumatic diseases. Ann Rheum Dis 2023;82(Suppl 1):1899-1900. doi: 10.1136/annrheumdis-2023-eular-4378.


87. Kaltsonoudis E, Pelechas E, Tziortzioti Z, Migkos M, Dimitroulas T, Kougkas N, Drosos AA, Voulgari PV. The value of the current diagnostic tools in the diagnosis of inflammatory myopathies: a multi-centre study. Ann Rheum Dis 2023;82(Suppl 1):1681-82 doi: 10.1136/annrheumdis-2023-eular-4803.


88. Pelechas E, Kougkas N, Drosos AA, Voulgari PV, Kaltsonoudis E. Similarities and differences between juvenile idiopathic arthritis and adult rheumatoid arthritis. Data from two university centres. Paediatric Rheumatol 2023;21(Suppl 2):P275 (IF: 3,0)


89. Venetsanopoulou AI, Mavridou K, Pelechas E, Voulgari PV, Drosos AA. Development of Morphea Following Treatment with an ADA Biosimilar: A Case Report. Curries Rheumatic Rev. 2024 Jan 12. Doi: 10.2174/0115733971266803231117072453


90. Pelechas E, Kaltsonoudis E, Migkos MP, Koletsos N, Karagianni PG, Drosos AA, Voulgari PV. State of the art review on the treatment of psoriatic disease. Mediterr J Rheumatol 2024; in Press (IF: 1,19)

Publications in scientific journals